Quince Therapeutics (QNCX) grants CBO 365,000 stock options

Rhea-AI Filing Summary

Quince Therapeutics reported an insider equity award for executive Brendan Hannah, who serves as CBO, COO and CCO. On January 23, 2026, he received an employee stock option to buy 365,000 common shares at an exercise price of $3.08 per share, with the option expiring on January 23, 2036. The filing shows he holds 365,000 derivative securities after this grant, all owned directly.

The option vests in 48 equal monthly installments, with 1/48 of the shares vesting on the grant date and the remaining portions vesting on the first day of each subsequent month until full vesting on December 1, 2029. This reflects routine equity-based compensation for a senior officer rather than an open-market share purchase or sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hannah Brendan

(Last) (First) (Middle)

C/O QUINCE THERAPEUTICS, INC.

611 GATEWAY BLVD., SUITE 273

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quince Therapeutics, Inc. [ QNCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CBO, COO & CCO

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$3.08	01/23/2026		A			365,000	(1)	01/23/2036	Common Shares	365,000	$0	365,000	D

Explanation of Responses:

1. The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting with 1/48th vesting on the date of grant and the remaining options vesting on the 1st day of each subsequent month, such that the total number of shares shall be fully vested on December 1, 2029.

	/s/ Brendan Hannah	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Quince Therapeutics (QNCX) report for Brendan Hannah?

Quince Therapeutics reported that executive Brendan Hannah received an employee stock option on January 23, 2026 covering 365,000 common shares of the company.

What is the exercise price and term of the new Quince (QNCX) stock options?

The employee stock option granted to Brendan Hannah has an exercise price of $3.08 per share and an expiration date of January 23, 2036.

How do the Quince Therapeutics (QNCX) options granted to Brendan Hannah vest?

The options vest in 48 equal monthly installments: 1/48 vests on the grant date, and the remaining installments vest on the first day of each subsequent month until the award is fully vested on December 1, 2029.

How many Quince (QNCX) derivative securities does Brendan Hannah hold after this Form 4 transaction?

After the reported grant, Brendan Hannah beneficially owns 365,000 derivative securities (employee stock options), held in direct ownership.

Is the Quince Therapeutics (QNCX) Form 4 transaction a purchase or sale of common stock?

No common stock was bought or sold in the market. The Form 4 reflects the grant of an employee stock option, not an open-market transaction in Quince common shares.

What is Brendan Hannah’s role at Quince Therapeutics (QNCX) according to the Form 4?

According to the filing, Brendan Hannah is an officer of Quince Therapeutics, serving as CBO, COO & CCO.